Unlock instant, AI-driven research and patent intelligence for your innovation.

The method for preparing tolvaptan intermediate

A purification method and compound technology, applied in the field of medicine, can solve the problems of cumbersome process, low overall yield of synthetic formula II compound, laborious and laborious cost, etc.

Active Publication Date: 2020-11-17
FUJIAN SHENGDI PHARM CO LTD +1
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] Among them, the post-treatment of this method adopts column chromatography to purify the compound of formula II, the process is cumbersome, laborious and costly, and the overall yield of the compound of formula II synthesized in the literature is low

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • The method for preparing tolvaptan intermediate
  • The method for preparing tolvaptan intermediate
  • The method for preparing tolvaptan intermediate

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Example 1: 7-chloro-1,2,3,4-tetrahydro-1-(2-methyl-4-aminobenzoyl)-5H-1-benzazepine-5-one ( Formula III) Preparation

[0042] Add 60kg of methanol, 40kg of tetrahydrofuran and 40kg of concentrated hydrochloric acid into the reaction kettle, stir and add 10.4kg of 7-chloro-1,2,3,4-tetrahydro-1-(2-methyl-4-nitrobenzoyl) -5H-1-Benzazepin-5-one (compound of formula IV). Dissolve 25kg of dihydrate and stannous chloride in 40kg of methanol, add to the above system, heat to 50-60°C, the reaction time is 2-2.5 hours, and the reaction ends. Concentrate under reduced pressure to remove the organic solvent, and put the material into a material bucket to freeze overnight. Shake filter and beat with tetrahydrofuran, shake filter to dryness to obtain the compound of formula III.

Embodiment 2

[0043] Example 2: N-[4-[(7-chloro-2,3,4,5-tetrahydro-5-oxo-1H-1-benzazepine-1-yl)carbonyl]-3- Preparation of methylphenyl]-2-methylbenzamide (formula II)

[0044] Add 100 L of dichloromethane and 11.0 kg of pyridine into the reaction kettle, add the compound of formula III under stirring, and then add 7.0 kg of o-toluoyl chloride. After the addition, stir the reaction at 20-30° C., and check that the reaction is complete. 13.9kg crude tolvaptan was obtained by rejection filtration, the purity was 94.79%, and the impurity M was 0.36%.

[0045] Add the solid obtained in the previous step into 57 kg of ethyl acetate / dichloromethane / isopropyl ether (volume ratio 1:5:2) solvent, heat to 50°C-60°C and stir to dissolve, cool and crystallize, and shake off to obtain a white solid 10.1 kg, yield: 71.3%, purity: 99.8%, impurity M content 0.03%.

Embodiment 3

[0047] According to the purification method described in the examples of CN101273017, CN101817783 or CN102060769, the obtained sample yield and purity data are shown in Table 1.

[0048] Table 1

[0049]

[0050] in conclusion:

[0051] 1. The method described in CN101817783 (methanol / petroleum ether) cannot effectively obtain a high-purity compound of formula II, and the appearance of the obtained sample is yellow, and the impurity M in the sample cannot be effectively removed;

[0052] 2. Although the methods described in CN101273017 and CN102060769 can obtain relatively high-purity formula II compounds, the refining yield is low and the production cost is high; meanwhile, the methods of CN101273017 and CN102060769 have poor refining effects on impurities M in the samples, and the obtained samples cannot satisfy Raw material quality standards, the unknown single impurity limit is controlled below 0.1%; in addition, the obtained sample is light yellow or light yellow.

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
purityaaaaaaaaaa
Login to View More

Abstract

The invention provides a method for preparing a high-purity tolvaptan intermediate, and concretely provides a method for purifying a tolvaptan intermediate N-[4-[(7-chloro-2,3,4,5-tetrahydro-5-oxo-1H-1-benzazepine-1-yl)carbonyl]-3-methylphenyl]-2-methylbenzamide (formula II). A crude product containing the compound of formula II is recrystallized by an organic solvent composed of ester, haloalkaneand ether to preferably obtain the compound of formula II, having a purity of above 99.00%.

Description

technical field [0001] The invention belongs to the technical field of medicine, and relates to a method for preparing high-purity tolvaptan intermediate N-[4-[(7-chloro-2,3,4,5-tetrahydro-5-oxo-1H-1- Benzazepine-1-yl)carbonyl]-3-methylphenyl]-2-methylbenzamide. Background technique [0002] Tolvaptan (Tolvaptan) is a non-peptide selective antidiuretic hormone V2 receptor antagonist developed by Japan's OTSUKA company, which can selectively block renal tubular arginine vasopressin receptors, and has the ability to drain and not excrete sodium specialty. It can be used to treat hyponatremia caused by congestive heart failure, liver cirrhosis, and syndrome of hyposecretion of antidiuretic hormone. [0003] Tolvaptan chemical name: N-[4-[(5R)-7-chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl) Carbonyl]-3-methylphenyl]-2-methylbenzamide, the structural formula is as follows: [0004] [0005] A variety of tolvaptan preparation methods have been disclosed in the p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D223/16
CPCC07D223/16
Inventor 高军龙李鹏刘凯郭大鹏
Owner FUJIAN SHENGDI PHARM CO LTD